You are here

Our science / Clinical Trials / Find a Trial / NCT00895050

Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients

Back to Search Print Save as PDF Bookmark Trial

NCT00895050

Last updated on December 7, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Main Inclusion Criteria:

- Patients, male or female, over 18 years old.

- Patients diagnosed with RA according to investigator criteria

- Patients with a disease evolution >= 1 year

- Patients with > = 5 affected joints

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Exclusion Criteria:

- Patients with other muscle skeletal, rheumatic and/or degenerative diseases different
from RA.

- Patients who are taking part or have taken part in a clinical trial or in a study with
drugs within the last 12 months. Any condition that, in the investigator's judgment
would interfere with the subject's ability to comply with protocol requirements or
give informed consent.

NCT00895050
Pfizer
Completed
Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
NCT03387423
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
NCT03885037
All Genders
0+
Years
Tokyo,
Descriptive Information
Brief TitleStudy Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients
Official TitleImpact of the Use of a Computer-based Tools on the Clinical Management and Evolution of Patients With Rheumatoid Arthritis.
Brief SummaryThe primary purpose of this study is to evaluate a computer-based tool on the clinical management of patients with rheumatoid arthritis in Spain.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationPatients with RA treated in rheumatology offices
ConditionRheumatoid Arthritis
InterventionOther: Review of clinical records
Study Groups/Cohorts1
Patients diagnosed with RA
Intervention: Other: Review of clinical records
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: July 13, 2011)		321
Original Estimated Enrollment
 (submitted: May 6, 2009)		300
Actual Study Completion DateJanuary 2011
Actual Primary Completion DateJanuary 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

Main Inclusion Criteria:

  • Patients, male or female, over 18 years old.
  • Patients diagnosed with RA according to investigator criteria
  • Patients with a disease evolution >= 1 year
  • Patients with > = 5 affected joints

Exclusion Criteria:

Exclusion Criteria:

  • Patients with other muscle skeletal, rheumatic and/or degenerative diseases different from RA.
  • Patients who are taking part or have taken part in a clinical trial or in a study with drugs within the last 12 months. Any condition that, in the investigator's judgment would interfere with the subject's ability to comply with protocol requirements or give informed consent.
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesNot Provided
Removed Location CountriesSpain
 
Administrative Information
NCT NumberNCT00895050
Other Study ID Numbers0881X1-4576
B1801084
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJuly 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now